Letter to the editor: A contemporary assessment of CFTR modulator use and eligibility

Letter to the editor: A contemporary assessment of CFTR modulator use and eligibility

•ELX/TEZ/IVA has changed the treatment landscape for cystic fibrosis.•Estimates of undiagnosed prevalence of CF should be interpreted with caution.•We provide important context for estimating ELX/TEZ/IVA coverage and updated data.•Two/thirds of diagnosed eligible patients are treated with ELX/TEZ/IV...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cystic fibrosis 2024-03, Vol.23 (2), p.368-369
Hauptverfasser: Rubin, Jaime L., Kreindler, James L.
Format: Artikel
Sprache:eng
Schlagworte:
Chloride Channel Agonists - therapeutic use
Cystic Fibrosis - drug therapy
Cystic Fibrosis Transmembrane Conductance Regulator - genetics
Humans
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•ELX/TEZ/IVA has changed the treatment landscape for cystic fibrosis.•Estimates of undiagnosed prevalence of CF should be interpreted with caution.•We provide important context for estimating ELX/TEZ/IVA coverage and updated data.•Two/thirds of diagnosed eligible patients are treated with ELX/TEZ/IVA.
ISSN:1569-1993
1873-5010
DOI:10.1016/j.jcf.2024.02.014